Study guide
17.1 Demography, Fertility Rates & Family Welfare Indicators
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
17.1 Demography, Fertility Rates & Family Welfare Indicators
Key Takeaways Explain This Topic AI
Demographic cycle spans 5 stages; India is currently in the late expanding stage (Stage 3) with a declining Total Fertility Rate (TFR) reaching replacement level (2.0 in NFHS-5).
Key fertility metrics include Crude Birth Rate, General Fertility Rate, Age-Specific Fertility Rate, and Total Fertility Rate (replacement level TFR is 2.1).
Modern contraceptive methods are categorized into temporary (barrier, IUCDs including CuT-380A and LNG-20, combined oral pills, Ormeloxifene/Saheli, DMPA/Antara) and permanent (laparoscopic tubal occlusion, Non-Scalpel Vasectomy).
Pearl Index quantifies contraceptive failure rates per 100 woman-years of exposure, serving as the standard metric for efficacy evaluation.
Target Couple Protection Rate (CPR) required to achieve a Net Reproduction Rate (NRR) of 1 is approximately 60%.
Last updated: July 2026
17.1 Demography, Fertility Rates & Family Welfare Indicators
Demography is the scientific study of human populations, primarily focusing on their size, structure, development, and vital dynamics. For the UPSC Combined Medical Services (CMS) examination, a thorough understanding of demographic processes, fertility indicators, contraceptive technology, and family welfare program statistics is essential.
1. The Demographic Cycle and Demographic Transition
The demographic cycle describes the transformation of a population over time through changes in birth rates and death rates. It consists of five distinct stages:
Stage Name Birth Rate Death Rate Characteristics & Country Examples
Stage 1 High Stationary High High Population remains stable. High birth rate balanced by high infant & maternal mortality. (Historically pre-industrial; currently few isolated tribes).
Stage 2 Early Expanding High Declining Death rate drops rapidly due to improved sanitation, healthcare, and food supply, while birth rate stays high. Rapid population growth. (e.g., Many Sub-Saharan African countries).
Stage 3 Late Expanding Declining Low / Declining Birth rate begins to fall significantly due to urbanization, female literacy, and access to contraception. Death rate continues to decline or stays low. Population continues to grow but at a slower rate. ( India is currently in Stage 3 , transitioning toward Stage 4).
Stage 4 Low Stationary Low Low Birth rate and death rate are both low and equal. Population becomes stationary at a high level. Zero population growth (ZPG). (e.g., Denmark, UK, Sweden).
Stage 5 Declining Lower than Death Rate Low Birth rate falls below death rate. Natural decrease in population. (e.g., Japan, Germany, Italy, Russia).
Demographic Dividend
India is currently experiencing a window of Demographic Dividend , defined as the economic growth potential that results from shifts in a population's age structure, specifically when the proportion of the working-age population (15–64 years) is larger than the non-working-age dependent population (<15 years and ≥65 years).
2. Demographic Indicators and Formulas
Public health specialists use specific quantitative indicators to analyze fertility, mortality, and population structure.
A. Fertility Indicators
Crude Birth Rate (CBR) : CBR = Total number of live births during a given year Mid-year total population × 1000 \text{CBR} = \frac{\text{Total number of live births during a given year}}{\text{Mid-year total population}} \times 1000 CBR = Mid-year total population Total number of live births during a given year × 1000
Note : Called "crude" because the denominator includes the entire population (males, children, elderly) rather than just females of reproductive age.
General Fertility Rate (GFR) : GFR = Total number of live births in a year Mid-year female population aged 15–49 years × 1000 \text{GFR} = \frac{\text{Total number of live births in a year}}{\text{Mid-year female population aged 15--49 years}} \times 1000 GFR = Mid-year female population aged 15–49 years Total number of live births in a year × 1000
Significance : Better indicator than CBR as it restricts the denominator to women of childbearing age (15–49 years).
General Marital Fertility Rate (GMFR) : GMFR = Total number of live births in a year Mid-year married female population aged 15–49 years × 1000 \text{GMFR} = \frac{\text{Total number of live births in a year}}{\text{Mid-year married female population aged 15--49 years}} \times 1000 GMFR = Mid-year married female population aged 15–49 years Total number of live births in a year × 1000
Age-Specific Fertility Rate (ASFR) : ASFR = Live births to women in a specific age group in a year Mid-year female population of that specific age group × 1000 \text{ASFR} = \frac{\text{Live births to women in a specific age group in a year}}{\text{Mid-year female population of that specific age group}} \times 1000 ASFR = Mid-year female population of that specific age group Live births to women in a specific age group in a year × 1000
Clinical Note : In India, peak fertility is observed in the 20–24 years age group, followed by the 25–29 years group.
Total Fertility Rate (TFR) : TFR = 5 × ∑ i = 1 7 ASFR i ÷ 1000 \text{TFR} = 5 \times \sum_{i=1}^{7} \text{ASFR}_i \div 1000 TFR = 5 × i = 1 ∑ 7 ASFR i ÷ 1000
Definition : The average number of children that would be born alive to a woman during her lifetime if she were to pass through her childbearing years conforming to the age-specific fertility rates of a given year.
Replacement Level TFR : 2.1 (The extra 0.1 accounts for female mortality before reaching reproductive age and sex ratio imbalances).
National Status (NFHS-5, 2019-21) : India's TFR has declined to 2.0 nationally (Urban: 1.6, Rural: 2.1), reaching below replacement level.
Gross Reproduction Rate (GRR) : Definition : Average number of daughters that would be born to a woman if she passed through her reproductive years assuming current age-specific fertility rates, without accounting for female mortality .
Net Reproduction Rate (NRR) : Definition : Average number of daughters that would be born to a female child if she passed through her lifetime conforming to current age-specific fertility and mortality rates.
NRR = 1 : Indicates that each generation of mothers is exactly replacing itself (Replacement level).
Target Relationship : NRR = 1 corresponds to a Total Fertility Rate of 2.1 and a Couple Protection Rate (CPR) of ~60% .
B. Structural and Dependency Indicators
Sex Ratio : In India, defined as the number of females per 1,000 males . (NFHS-5 overall sex ratio: 1,020 females per 1,000 males; Sex Ratio at Birth: 929 per 1,000 males).
Child Sex Ratio : Number of females per 1,000 males in the 0–6 years age group.
Dependency Ratio : Dependency Ratio = Population (0–14 yrs) + Population ( ≥ 65 yrs) Population (15–64 yrs) × 100 \text{Dependency Ratio} = \frac{\text{Population (0--14 yrs)} + \text{Population (}\ge 65\text{ yrs)}}{\text{Population (15--64 yrs)}} \times 100 Dependency Ratio = Population (15–64 yrs) Population (0–14 yrs) + Population ( ≥ 65 yrs) × 100
Child Dependency Ratio : Pop (0–14) Pop (15–64) × 100 \frac{\text{Pop (0--14)}}{\text{Pop (15--64)}} \times 100 Pop (15–64) Pop (0–14) × 100
Aged Dependency Ratio : Pop ( ≥ 65 ) Pop (15–64) × 100 \frac{\text{Pop (}\ge 65\text{)}}{\text{Pop (15--64)}} \times 100 Pop (15–64) Pop ( ≥ 65 ) × 100
3. Contraceptive Technology and Family Welfare Methods
Contraceptive methods are divided into Temporary (Spacing) and Permanent (Terminal) methods.
- A. Temporary (Spacing) Contraceptive Methods
- 1. Barrier Methods
Male Condom (Nirodh) : Latex sheath. Provides dual protection: contraception and protection against Sexually Transmitted Infections (STIs)/HIV. Ideal for spacing and early marital life.
Female Condom (FC2) : Polyurethane/nitrile sheath with two rings.
Diaphragm & Cervical Cap : Vaginal barrier used with spermicidal jelly (Nonoxynol-9). Must be kept in place for at least 6 hours post-coitus.
2. Intrauterine Contraceptive Devices (IUCDs)
First Generation : Non-medicated IUCDs (e.g., Lippes Loop). Made of polyethylene with barium sulfate. Causes mild sterile endometrial inflammatory reaction.
Second Generation (Copper IUCDs) :
CuT-380A : Surface area of copper is 380 mm². Lifespan: 10 years . Approved for postpartum placement (within 48 hours) or interval placement.
CuT-375 : Lifespan: 5 years .
Mechanism of action : Copper ions exert spermicidal action by inhibiting sperm motility, viability, and acrosomal reaction; alters endometrial environment.
Third Generation (Hormone-Releasing IUCDs) :
Levonorgestrel-releasing IUD (LNG-20 / Mirena) : Releases 20 mcg of levonorgestrel per day. Lifespan: 5 to 8 years .
Mechanism : Cervical mucus thickening (blocks sperm entry), endometrial atrophy (prevents implantation).
Therapeutic Indication : Highly effective treatment for Idiopathic Heavy Menstrual Bleeding (Menorrhagia) and Endometriosis.
Side Effects & Complications of IUCDs :
Most common symptom/side effect: Bleeding and Pain (most common reason for removal).
Most dangerous complication: Uterine Perforation (highest risk during immediate postpartum insertion or un-experienced hands, incidence ~1 in 1000 insertions).
Infection: Pelvic Inflammatory Disease (PID) risk is highest in the first 20 days post-insertion ( Actinomyces israelii association).
Expulsion: Most common in the first few months, especially during menstruation.
3. Hormonal Contraception
Combined Oral Contraceptive Pills (COCPs) :
Composition under Government of India (Mala-N / Mala-D) : Ethinylestradiol (30 mcg) + Levonorgestrel (0.15 mg) .
Regimen : 21 active hormonal pills + 7 iron pills (Ferrous Fumarate 60 mg elemental iron) taken daily starting on Day 1 to Day 5 of the menstrual cycle.
Mechanism of Action : Primary mechanism is inhibition of ovulation by suppressing LH surge via negative feedback on the hypothalamus-pituitary axis. Secondary mechanisms: cervical mucus thickening and endometrial alteration.
Non-contraceptive benefits : Reduces risk of Ovarian Cancer and Endometrial Cancer (protective effect persists for years after stopping), reduces benign breast disease, dysmenorrhea, PID, and ectopic pregnancy.
Absolute Contraindications :
History of Venous Thromboembolism (DVT/PE) or thrombophilic disorders.
Ischemic heart disease, stroke, or severe hypertension (BP ≥160/100 mmHg).
Active liver disease, cirrhosis, or hepatocellular carcinoma.
Breast cancer (current or recent past).
Smokers aged >35 years who smoke ≥15 cigarettes/day.
Migraine with aura.
Centchroman / Ormeloxifene (Saheli / Chhaya) :
Non-hormonal, non-steroidal Selective Estrogen Receptor Modulator (SERM). Developed by Central Drug Research Institute (CDRI, Lucknow).
Dosage Regimen : Twice weekly for the first 3 months , followed by once weekly thereafter (e.g., Sunday and Wednesday for 3 months, then every Sunday).
Mechanism : Prevents implantation by creating asynchronous endometrial development and altering tubal motility. Ovulation is not suppressed.
Side Effect : Delayed menstruation (scanty or delayed periods in ~8-10% of users).
Injectable Contraceptives (Antara Program) :
Depot Medroxyprogesterone Acetate (DMPA) : Dose 150 mg Deep IM every 3 months (12 weeks) .
Mechanism : Suppresses LH surge, inhibiting ovulation; thickens cervical mucus.
Side Effects : Irregular bleeding, spotting, eventual amenorrhea (common after 1 year of use), slight delay in return of fertility (6–9 months), mild drop in bone mineral density.
Emergency Contraception :
Levonorgestrel (LNG 1.5 mg single dose) : Must be taken as soon as possible within 72 hours of unprotected coitus. Suppresses or delays ovulation. Ineffective after implantation has occurred.
Ulipristal Acetate (30 mg single dose) : Selective progesterone receptor modulator effective up to 120 hours (5 days) .
Copper T 380A : Most effective emergency contraceptive; inserted within 5 days of unprotected coitus (failure rate <0.1%).
- B. Permanent (Terminal) Contraceptive Methods
- 1. Female Sterilization (Tubal Ligation)
Techniques: Modified Pomeroy's technique (minilaparotomy) or Laparoscopic tubal occlusion using Falope rings / Filshie clips.
Timing: Postpartum (within 7 days, ideally 24–48 hours post-delivery) or Interval (after 6 weeks post-delivery).
2. Male Sterilization (Non-Scalpel Vasectomy - NSV)
Technique: Puncture technique developed by Li Shunqiang; vas deferens is isolated, ligated, and occluded without skin incision.
Post-Procedure Criteria for Sterility : The male is not immediately sterile . Must use alternative contraception (e.g., condoms) for at least 3 months or until 2 consecutive semen analyses confirm azoospermia (or ~30 ejaculations).
4. Evaluation of Contraceptive Efficacy: Pearl Index
The efficacy of a contraceptive method is evaluated using the Pearl Index : Pearl Index = Total number of accidental pregnancies Total months of exposure (or woman-months of use) × 1200 \text{Pearl Index} = \frac{\text{Total number of accidental pregnancies}}{\text{Total months of exposure (or woman-months of use)}} \times 1200 Pearl Index = Total months of exposure (or woman-months of use) Total number of accidental pregnancies × 1200
Note : The factor 1200 converts woman-months of use into 100 woman-years of exposure (since 100 women × 12 months = 1,200 months).
Interpretation : Represents the number of failure pregnancies per 100 woman-years of use. A lower Pearl Index indicates a more effective contraceptive method.
Typical Pearl Index values:
- Implants (Nexplanon): ~0.05
- Vasectomy: ~0.15
- LNG-20 IUD / CuT-380A: ~0.2–0.8
- Combined Oral Pills (typical use): ~3–7
- Condoms (typical use): ~12–13
- Natural / Rhythm Method: ~20–24